Staying Positive During the Pandemic

The good news for patients in need of outpatient surgery is that, across the country, health care providers and policymakers have recognized that elective surgery is not the same thing as optional surgery and are allowing ASCs to remain open to provide this care.

Handling of Explanted Medical Devices Addressed in AORN’s Revised Guideline for Specimen Management

SP professionals must manage explants safely and properly any time a request is made to sterilize an explanted device, such a screw, hip, plate and so on, for return to the patient.

Disinfection Methods – Straightforward or Complicated?

With all the different cleaning, disinfecting and sterilizing processes that go on inside of hospitals, I find disinfection to be the most complex and complicated among them.

Steam Sterilization Standard ST79 Receives Community-Driven Update

After three years, a widely used standard in health care and industry has undergone an important update.

STERIS Acquires Key Surgical

STERIS plc has signed a definitive agreement to purchase Key Surgical, a portfolio company of Water Street Healthcare Partners LLC, through a U.S. subsidiary for $850 million. STERIS anticipates that the acquisition will qualify for a tax benefit related to tax deductible goodwill. Adjusting for the present value of the anticipated tax benefit, the purchase price is effectively reduced to approximately $810 million. Key Surgical, founded in 1988, is a global provider of consumable products serving hospitals and surgical facilities. Annual revenue for Key Surgical in calendar 2020 is anticipated to be approximately $170 million, with adjusted EBIT of approximately $50 million.

“Key Surgical strengthens, complements and expands STERIS’s product offering and reach around the globe. Their focus on the sterile processing department, operating room and endoscopy fits perfectly with our core health care customers,” said Walt Rosebrough, president and chief executive officer of STERIS. “The business has demonstrated an ability to grow at rates above industry levels with its product portfolio breadth, a steady stream of new products and a highly effective commercial model. We welcome the Key Surgical people to the STERIS team, and we look forward to working together to enhance our service to our customers and the value for our shareholders.”

“Our companies are a great fit – we truly complement and strengthen STERIS’s product offering around the globe. Over the last 32 years, Key Surgical has developed a strong brand with a diverse product portfolio, continual expansion of new products and effective commercial model. We’re excited and look forward to the great potential this combination brings.” Rosebrough added.

Under the terms of the agreement, STERIS will purchase the shares of Key Surgical at closing. The transaction will be financed through a combination of debt and cash on hand and is anticipated to close by December 31, 2020 pending customary closing conditions and regulatory approval. The transaction is expected to be immediately accretive to STERIS’s adjusted earnings after close and add approximately $40 million to revenue and about $0.10 to adjusted earnings per diluted share in STERIS’s fiscal 2021 fourth quarter. STERIS expects to realize annualized pre-tax earnings synergies of $10-$15 million by year three following the close.



Submit a Comment

Your email address will not be published. Required fields are marked *